NantKwest Augments, Strengthens Senior Management Team
23 9월 2015 - 12:00AM
Business Wire
--Company Adds Clinical Development,
Medical Affairs and M&A Executives--
NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy
company focused on harnessing the power of the innate immune system
by using natural killer cells to treat cancer, infectious diseases
and inflammatory diseases, today announced the appointments of
three senior-level executives: Andreas Niethammer, M.D., Ph.D., as
executive medical director; Dvorit Samid, Ph.D., as senior vice
president of medical affairs; and, Jerel A. Banks, M.D., Ph.D., as
senior vice president mergers and acquisitions.
“With these appointments, we have substantially augmented and
strengthened our senior management team with accomplished
executives,” said Patrick Soon-Shiong, M.D., chairman and chief
executive officer of NantKwest. “Drs. Niethammer, Samid and Banks
bring deep and relevant expertise, knowledge and experience in
critical roles to our organization, as well as strong leadership
and strategic direction to help propel NantKwest forward.”
Most recently, Dr. Niethammer was vice president clinical
development immune oncology for privately held Poseida
Therapeutics. He is an associate professor of oncology at
Ruprecht-Karls-Universitaet Heidelberg (Heidelberg University) and
co-founded Vaximm AG, a Swiss-based company focused on oral
vaccines for cancer and infectious diseases. Previously, Dr.
Niethammer was vice president clinical development for Tocagen, a
clinical-stage biopharmaceutical company, and before that served in
senior level roles with Pfizer, Eli Lilly and Company and ImClone,
where he focused on cancer immunotherapy and drug development.
Dr. Samid has more than 30 years of oncology research and drug
development experience. She most recently served as vice president
of medical affairs for Synta Pharmaceuticals, after holding similar
positions with several other pharmaceutical companies, including
ImClone Systems, Allos Therapeutics, Abraxis Oncology and
Hoffman-La Roche. Prior to joining pharma, Dr. Samid was an
associate professor at the University of Virginia’s Cancer Center
and a section chief for the National Cancer Institute. Dr. Samid
earned a doctorate degree in Cell Biology from Catholic University
of America in Washington, D.C. and a Bachelor of Science degree in
Microbiology from Hebrew University in Jerusalem, Israel. She has
authored more than 80 publications in oncology and holds 19
patents.
Prior to joining NantKwest, Dr. Banks served as vice president,
portfolio manager and research analyst for the Franklin
Biotechnology Discovery Fund at Franklin Templeton Investment.
Previously, he worked as a senior equity research analyst covering
the biotechnology sector at Sectoral Asset Management Inc. and
Apothecary Capital. Before that Dr. Banks was an equity research
associate on the healthcare investment team at Capital Research and
Management. Dr. Banks earned an M.D. and Ph.D. in Organic Chemistry
from Brown University and holds a B.A. in Chemistry from Princeton
University.
About NantKwest Inc.
NantKwest (Nasdaq:NK) is a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact, (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody, and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies including the reduction of risk of serious
"cytokine storms" reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest's NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest's NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150922005540/en/
NantKwestJen Hodson, 562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024